Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorAin Shams University
About this trial
The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients.
The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life.
Participants will receive either vinpocetine or placebo, twice daily for 3 months.
Eligibility criteria
Qualifiers
Age ≥ 18 years,
Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml/min) or stage 4 (eGFR 15-29 ml/min),
Albumin/Creatinine ratio (ACR): 30 - 300 μg /mg (microalbuminuria),
Stable standard therapy for at least three months prior to inclusion in the study.
Disqualifiers
Kidney donor or recipient,
Active malignancy,
Pregnancy or breastfeeding,
Known intolerance or hypersensitivity to VPN,
Trial design
Treatments tested in this trial
- Vinpocetine
- Standard Therapy
- Placebo
Treatment groups
64 Participants
are divided into 2 treatment groupsLocations
2Ain Shams University Hospital11588, CairoAbbasseia, Egypt
Ain Shams Hospitals11588, CairoAbbasseya, Egypt
Sponsors and collaborators
Ain Shams University
Lead sponsor
Source ClinicalTrials.gov